Concepedia

Corina Loghin

CL

12

Publications

1.6K

Citations

11

H-Index

2004

Active since

Affiliations

Eli Lilly (United States)(Current)

Corina Loghin is an author at Eli Lilly (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2004–2022

12

Publications

12

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 766 citations · Full text

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 246 citations · Full text

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( <scp>GLP</scp> ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <scp>long‐acting GLP</scp> ‐1 receptor agonists

Shweta Urva, Tamer Coşkun, Corina Loghin et al. · Diabetes Obesity and Metabolism · 2020 · 116 citations · Full text

Clinical Assessment of Norepinephrine Transporter Blockade Through Biochemical and Pharmacological Profiles

Simi Vincent, P. R. Bieck, Emily M. Garland et al. · Circulation · 2004 · 100 citations · Full text

Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials

Jeanne S. Geiser, Michael Heathman, Xuewei Cui et al. · Clinical Pharmacokinetics · 2015 · 94 citations

, , +7

Rows per page

1–5 of 12